Neurogene Inc. (NASDAQ:NGNE) Given Consensus Recommendation of "Moderate Buy" by Brokerages
2026-04-04 06:40:44 ET
Shares of Neurogene Inc. ( NASDAQ:NGNE – Get Free Report ) have been assigned an average recommendation of “Moderate Buy” from the seven research firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $44.00.
NGNE has been the topic of a number of recent research reports. Wall Street Zen lowered Neurogene from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. HC Wainwright reaffirmed a “buy” rating and set a $70.00 price target on shares of Neurogene in a research note on Tuesday, January 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neurogene in a report on Thursday, January 22nd. Lifesci Capital initiated coverage on shares of Neurogene in a report on Monday, January 26th. They set an “outperform” rating and a $50.00 target price for the company. Finally, Canaccord Genuity Group assumed coverage on shares of Neurogene in a research note on Friday, February 27th. They issued a “buy” rating on the stock.
Check Out Our Latest Stock Analysis on NGNE
Insider Buying and Selling
In other news, insider Stuart Cobb sold 6,797 shares of Neurogene stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $20.81, for a total value of $141,445.57. Following the completion of the transaction, the insider owned 30,497 shares of the company’s stock, valued at $634,642.57. This trade represents a 18.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link . Also, CFO Christine Mikail Cvijic sold 4,045 shares of the company’s stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $20.81, for a total transaction of $84,176.45. Following the completion of the sale, the chief financial officer directly owned 105,798 shares in the company, valued at approximately $2,201,656.38. The trade was a 3.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 11.64% of the stock is owned by company insiders.
Institutional Investors Weigh In On Neurogene
A number of large investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets raised its position in shares of Neurogene by 89.8% in the third quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock valued at $36,000 after purchasing an additional 978 shares during the period. PNC Financial Services Group Inc. grew its stake in Neurogene by 24.7% in the 3rd quarter. PNC Financial Services Group Inc. now owns 5,055 shares of the company’s stock valued at $88,000 after buying an additional 1,000 shares during the last quarter. ADAR1 Capital Management LLC raised its holdings in Neurogene by 3.4% in the 3rd quarter. ADAR1 Capital Management LLC now owns 30,633 shares of the company’s stock valued at $531,000 after acquiring an additional 1,008 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Neurogene by 17.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock worth $82,000 after acquiring an additional 1,059 shares during the last quarter. Finally, Daiwa Securities Group Inc. bought a new stake in shares of Neurogene during the fourth quarter worth approximately $66,000. Institutional investors own 52.37% of the company’s stock.
Neurogene Price Performance
Shares of NGNE stock opened at $20.69 on Friday. Neurogene has a 12-month low of $6.88 and a 12-month high of $37.27. The firm has a fifty day moving average of $19.75 and a 200-day moving average of $21.71. The company has a market capitalization of $322.14 million, a price-to-earnings ratio of -4.88 and a beta of 1.56.
Neurogene ( NASDAQ:NGNE – Get Free Report ) last announced its earnings results on Tuesday, March 24th. The company reported ($1.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.08. On average, equities analysts expect that Neurogene will post -4.27 EPS for the current year.
Neurogene Company Profile
( Get Free Report )
Neurogene, Inc is a clinical?stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno?associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.
Neurogene’s proprietary AAV9?based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.
See Also
NASDAQ: NGNE
NGNE Trading
-2.63% G/L:
$26.29 Last:
32,731 Volume:
$26.52 Open:
